Immune effects of blood transfusion

Current Opinion in Hematology

Volumn 6, Issue 6, 1999, Pages 442-445

  Smit Sibinga, Cees Th ^a  

^a Sanquin Bloedbank Regio Nordoost Groningen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIGEN; FAS LIGAND; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

APOPTOSIS; ARTICLE; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; CELL VIABILITY; CLONAL ANERGY; FEVER; HLA SYSTEM; HUMAN; LEUKOCYTE TRANSFUSION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

BLOOD TRANSFUSION; HUMANS; HYPERSENSITIVITY;

EID: 0032693214     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199911000-00016     Document Type: Article

References (10)

1. Of special interest Of outstanding interest 1 Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, et al.: Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999, 93:1770-1777. This article provides a new and highly interesting view on how allogeneic blood transfusions possibly could cause immunmodulatory effects. Despite the fact that the work reported is ex vivo, the data are promising and fit in the scientific modeling of immune effects following transfusion of allogeneic blood.
2. 2 Douillard P, Vignes C, Josien R, Chiffoleau E, Heslan JM, Proust V, et al.: Reassessment of the role of CD8+ T cells in the induction of allograft tolerance by donor-specific blood transfusion. Eur J Immunol 1999, 29:1919-1924.
3. 3 Strauss RG, Cordle DG, Quijana J, Goeken NE: Comparing alloimmunization in preterm infants after transfusion of fresh unmodified versus stored leukocyte-reduced red blood cells. J Pediatr Hematol Oncol 1999, 21:224-230.
4. 4 Rules Governing Medicinal Products in the European Community: Guide to Good Manufacturing Practice for Medicinal Products. Brussels, Luxembourg: Commission of the European Communities; 1989. [ECSC-EEC-EAEC.]
5. 5 Mincheff M: Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox Sang 1998, 74(suppl 2):189-200. This overview presents a concise state of the art of the dynamic changes of stored leukocytes and related implications on post-transfusion immunomodulation and other transfusion associated phenomena.
6. 6 Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J: Extreme leukoreduction of major histocompatibllity complex class II positive B cells enhances allogeneic platelet immunity. Blood 1999, 93:713-720.
7. 7 Blajchman MA: Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 1998, 74(suppl 2):315-319.
8. 8 Heddle NM, Klama L, Meyer R, Walker I, Boshkov L, Roberts R, et al.: A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999, 39:231-238.
9. 9 Novotny VMJ, van Doorn R, Witvliet MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells. Blood 1995, 85:1736-1741.
10. 10 De Wolf JThM, Westerterp-Maas A, Hepkema BG, Lems SPM, Plantinga O, Das PC, Smit Sibinga CTh: Alternative approaches to prevention of alloimmunization: a virtue of reality? In Risk Factors in Blood Transfusion: A Virtue of Reality. Edited by Smit Sibinga CTh, Alter HJ. Dordrecht; Kluwer Academic Publishers; 1999 (in press). The authors are the first to clinically study the immunostimulatory and modulatory effects of aged leukocytes in red cell and platelet concentrates, and show indeed a weakening of the antigen presentation and related recipient response in a large prospective cohort of hematology patients.